Australia's Orthocell rises on strong June quarter revenue, upbeat US outlook

Orthocell

01/07/2025 05:00

** Orthocell shares OCC.AX rise 7.2% to A$1.260

** Fourth top performer in ASX All Ordinaries Index .AORD

** Regenerative medicine company reports June quarter revenue of A$2.73 mln ($1.79 mln), up 22.8% Q/Q and 48.4% Y/Y

** Revenue driven by sales of flagship nerve repair product, Remplir, in Australia

** U.S. sales of Remplir not included in June quarter revenue numbers; expects U.S. sales to ramp up during 1H26

($1 = 1.5225 Australian dollars)

 (Reporting by Anjali Singh in Bengaluru)

 ((anjali.singh2@thomsonreuters.com))